Biohaven Pharmaceutical Holding EBITDA 2016-2022 | BHVN
Biohaven Pharmaceutical Holding annual and quarterly EBITDA history from 2016 to 2022. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- Biohaven Pharmaceutical Holding EBITDA for the quarter ending March 31, 2022 was $-0.049B, a 78.57% decline year-over-year.
- Biohaven Pharmaceutical Holding EBITDA for the twelve months ending March 31, 2022 was $-0.498B, a 30.44% decline year-over-year.
- Biohaven Pharmaceutical Holding 2021 annual EBITDA was $-0.679B, a 6.79% increase from 2020.
- Biohaven Pharmaceutical Holding 2020 annual EBITDA was $-0.636B, a 32.91% increase from 2019.
- Biohaven Pharmaceutical Holding 2019 annual EBITDA was $-0.478B, a 117.29% increase from 2018.
Biohaven Pharmaceutical Holding Annual EBITDA
(Millions of US $) |
| 2021 |
$-679 |
| 2020 |
$-636 |
| 2019 |
$-478 |
| 2018 |
$-220 |
| 2017 |
$-108 |
| 2016 |
$-61 |
| 2015 |
$-10 |
Biohaven Pharmaceutical Holding Quarterly EBITDA
(Millions of US $) |
| 2022-03-31 |
$-49 |
| 2021-12-31 |
$-149 |
| 2021-09-30 |
$-134 |
| 2021-06-30 |
$-166 |
| 2021-03-31 |
$-231 |
| 2020-12-31 |
$-166 |
| 2020-09-30 |
$-160 |
| 2020-06-30 |
$-159 |
| 2020-03-31 |
$-151 |
| 2019-12-31 |
$-135 |
| 2019-09-30 |
$-90 |
| 2019-06-30 |
$-199 |
| 2019-03-31 |
$-54 |
| 2018-12-31 |
$-48 |
| 2018-09-30 |
$-55 |
| 2018-06-30 |
$-38 |
| 2018-03-31 |
$-83 |
| 2017-12-31 |
$-28 |
| 2017-09-30 |
$-40 |
| 2017-06-30 |
$-25 |
| 2017-03-31 |
$-14 |
| 2016-12-31 |
$-23 |
| 2016-09-30 |
$-28 |
| 2016-06-30 |
$-7 |
| 2016-03-31 |
$-3 |
| 2015-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$10.057B |
$0.463B |
|
Biohaven Pharmaceutical is a commercial-stage biotechnology company focused on developing, and commercializing products, primarily in the fields of central nervous system diseases, including neurological and rare disorders.
|
